Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, May 2000, p. 366-370, Vol. 7, No. 3
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Induction of Hypergammaglobulinemia and Macrophage Activation
by Silicone Gels and Oils in Female A.SW Mice
J. O.
Naim,1,*
M.
Satoh,2
N. A.
Buehner,1
K. M. L.
Ippolito,1
H.
Yoshida,2
D.
Nusz,1
L.
Kurtelawicz,1
S. F.
Cramer,3 and
W.
H.
Reeves2
Departments of
Surgery1 and
Pathology,3 Rochester General Hospital,
Rochester, New York 14621, and Division of Rheumatology and
Clinical Immunology, University of Florida, Gainesville, Florida
326102
Received 25 October 1999/Returned for modification 10 December
1999/Accepted 18 January 2000
 |
ABSTRACT |
Although most published epidemiological studies have found little
evidence of systemic autoimmune disease associated with silicone breast
implants, there still remains a question of whether silicones can cause
local and/or systemic immune dysfunction. This study further
investigates the effects of silicones on autoantibody and
immunoglobulin production and macrophage activation in female A.SW
mice. Sixty mice were divided among four treatment groups receiving a
0.5-ml intraperitoneal injection of either phosphate-buffered saline
(PBS), pristane, silicone gel, or silicone oil. Test bleeds were taken
periodically for 6 months. In contrast to pristane, neither silicone
gel nor silicone oil induced lupus-associated antinuclear
autoantibodies (immunoglobulin G [IgG] anti-nRNP/Sm, Su, and
ribosomal P) or lupus nephritis. However, serum IgM became elevated
persistently within 1 month of silicone gel or silicone oil
administration. Also, the level of IgG3 was clearly elevated in
silicone oil-treated mice. In contrast, IgG1, IgG2a, and IgG2b levels
were not affected greatly by either silicone gel or oil. Furthermore,
peritoneal macrophages from silicone- and pristane-treated mice
produced higher levels of interleukin-1
(IL-1
) and IL-6 than
those from PBS-treated mice after lipopolysaccharide stimulation. These
results suggest that silicone gels and oils are capable of inducing
hypergammaglobulinemia and activating macrophages in female A.SW mice.
 |
INTRODUCTION |
The relative safety of silicone
breast implants (SBI) has been and continues to be controversial. Most
published epidemiological studies have found little, if any, evidence
of systemic autoimmune disease associated with SBI (2, 3, 6, 14,
17). However, many of these retrospective studies were limited to
detecting an increased frequency of classic autoimmune and/or
clinically defined diseases. The question remains whether susceptible
individuals may develop an ill-defined immunological syndrome as a
result of silicone exposure. The present study represents an effort to further examine the effects of silicones on immune function under defined experimental conditions.
Silicone is the generic description for synthetic polymers containing a
repeating Si-O backbone and organic groups attached to the silicon atom
(7). Medical-grade silicones consist primarily of
polydimethylsiloxane (PDMS), which is a synthetic polymer having (CH3)2SiO as its repeating unit. Depending upon
the number of repeat units in the polymer chain and the degree of
cross-linking, medical-grade silicones can be found as a fluids (oils),
gels, or elastomers. Silicone oils are straight chains of PDMS, which are chain terminated with trimethylsilyl groups and come in a variety
of viscosities (7). Silicone gels are lightly cross-linked PDMS matrixes which produce three-dimensional networks that are swollen with PDMS fluids. Silicone elastomers are highly
cross-linked polymers to which amorphous silica has been added to
give greater tensile strength. All SBI are made up of a silicone
elastomer envelope which contains either silicone gel filler or saline.
Over the past several years our laboratory has shown that certain forms
of silicone are immunologically active. Silicone gel is a potent
humoral adjuvant and a weak adjuvant for cell-mediated immunity
(CMI) (9). Low-molecular-weight (low-MW) silicone oils
are weak adjuvants, whereas the highest-MW and most viscous oil
tested showed significant humoral adjuvant properties (10). Silicone gel when mixed with bovine type II collagen is arithritogenic in female DA rats (11). Silicone elastomer, preadsorbed with plasma proteins, activates human monocytes/macrophages in vitro to
secrete interleukin-1
(IL-1
), IL-6, and tumor necrosis factor alpha (TNF-
) (13). Also, recent work by McDonald et al.
has demonstrated that silicone gel enhances the development of
autoimmune disease in NZB mice and has little effect on BALB/c mice
(8). Thus, there is substantial evidence that silicones have
an effect on immune cells.
Like BALB/c (H-2b) mice, the A.SW
(H-2s) mice do not develop spontaneous
autoimmunity, making this strain an appropriate model for investigating
the immune effects of silicones. In view of the higher prevalence of
autoimmunity in women (22) and the preponderance of women
receiving SBI, we studied female mice only. We report here on the
induction of hypergammaglobulinemia and macrophage activation in female
A.SW mice by silicone gels and oils. Also, since silicone gels and oils
have been shown to be weak CMI adjuvants (9, 10), only
humoral immunity was examined here.
 |
MATERIALS AND METHODS |
Sixty female (6- to 8-week-old) A.SW
(H-2s-T18b-/SnJ) mice were obtained
from The Jackson Laboratory (Bar Harbor, Maine) and were divided
equally among four treatment groups as follows: phosphate-buffered saline (PBS) (negative control), pristane
(2,6,10,14-tetramethylpentadecane; Sigma, St. Louis, Mo.)
(positive control), silicone gel (Silastic II Mammary Implant, lot
HH019581; Dow Corning, Midland, Mich.), and silicone oil (360 Medical
Fluid 1000cs; Dow Corning). The silicone gel was aseptically removed
from an unused mammary implant and was churned with a Brinkman tissue
homogenizer to help reduce the gel's viscosity to facilitate
injection. Mice received a single 0.5-ml intraperitoneal injection of
one of the three materials or an equal volume of PBS. Prior to
injection, a pretest bleed (time zero) was taken via orbital puncture,
after which blood samples were obtained monthly for 6 months. Serum
from each mouse was stored at
70°C until analyzed. All mice were
housed under conventional conditions. At 6 months after injection mice
were anesthetized and euthanized by cervical dislocation, after which peritoneal macrophages were collected by lavage from some mice. The
kidneys were excised, and one was fixed in formalin, while the other
was snap frozen in liquid nitrogen and stored at
70°C.
Immunoprecipitation.
Six-month sera were screened for
autoantibodies to the Su and nRNP/Sm antigens by immunoprecipitation by
using [35S]methionine-[35S]cysteine-labeled
K562 cell extracts and 3.0 µl of mouse serum as described previously
(19).
Fluorescent antinuclear antibody (FANA).
Indirect
immunofluorescence of autoantibodies to nuclear and cytoplasmic
antigens was determined by using methanol-fixed HeLa cells as described
previously with some modifications (18). Briefly, cells were
incubated for 30 min with a 1:40 dilution of mouse serum, washed three
times with PBS, and then incubated for 30 min with a 1:40 dilution of
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG
(gamma-chain specific; Southern Biotechnology Associates). After being
washed, the cells were viewed with an epifluorescence microscope.
ELISAs for IgG anti-chromatin, IgG anti-ssDNA antibodies, and
antiribosomal P antibodies.
Immunoglobulin G (IgG) anti-chromatin
antibodies were measured as previously described (1). In
brief, wells of microtiter plates (Maxisorp; Nunc, Naperville, Ill.)
were coated with 100 µl of a 1-µg/ml concentration of chicken
chromatin antigens in borate-buffered saline. Sera were tested at a
1:500 dilution, followed by alkaline phosphatase-labeled goat
anti-mouse IgG (1:1,000) and p-nitrophenyl phosphate
substrate (Sigma). The optical density (OD) was measured at 405 nm by
using a Molecular Devices (Menlo Park, Calif.) enzyme-linked
immunosorbent assay (ELISA) plate reader. Antibodies to single-stranded
DNA (ssDNA) were measured as described previously (20).
Briefly, antibodies to heat-denatured calf thymus DNA (Sigma) were
detected with a 1:500 dilution of mouse sera and alkaline
phosphatase-conjugated goat anti-mouse IgG or IgM antibodies. The
absorbance at 405 nm of each sample for anti-ssDNA and anti-chromatin
antibodies was converted into units based on a standard curve produced
by pooled sera from MRL/lpr mice. The units were assigned as
follows: 1:500 dilution, 1,000 U; 1:5,000 dilution, 100 U;
1:50,000 dilution, 10 U; 1:500,000 dilution, 1 U; 1:5,000,000
dilution, 0.1 U; and 1:50,000,000 dilution, 0.01 U. Antiribosomal P
antibodies were detected by ELISA using a 22-amino-acid C-terminal
peptide as the antigen (18). The results were expressed as
the number of mice producing a positive antibody response that was
defined as an antibody unit value exceeding the mean plus three
standard deviations (SD) of the PBS-treated mice.
Measurement of IgM and IgG.
Total levels of each
immunoglobulin isotype were determined by ELISA (5).
Microtiter plate wells were coated for 12 h at 4°C with 50 µl
of a 3-µg/ml concentration of goat anti-mouse
- or
-light-chain
antibodies per well (9:1 ratio; Southern Biotechnology) in 20 mM Tris
(pH 8.0). Wells were washed with 0.15 M NaCl-2 mM EDTA-50 mM Tris
(NET) containing 0.3% Nonidet P-40 (NET-NP-40) and then blocked with
0.5% bovine serum albumin (BSA) in NET-NP-40. Mouse sera were diluted
1:200,000 with NET-NP-40 containing 0.5% BSA and added to the wells
for 12 h at 4°C. Immunoglobulin isotype standards (IgG1, IgG2a,
IgG2b, IgG3, and IgM [Southern Biotechnology], each at 100 µg/ml,
with a 12-h incubation at 4°C) were used for standard curve fitting
at concentrations of 100, 50, 25, 10, 5, 2.5, 1, and 0.5 ng/ml. After
being washed, the wells were incubated with a 1:1,000 dilution of
alkaline phosphatase-labeled goat anti-mouse antibodies specific for
IgG1, IgG2a, IgG2b, IgG3, or IgM (Southern Biotechnology);
p-nitrophenyl phosphate substrate was then added, and the OD
was determined at 405 nm. Statistical analysis was performed by using
SigmaStat statistical software (SPSS, Inc., Chicago, Ill.) employing
the one-way analysis-of-variance technique applying multiple comparison corrections.
Peritoneal macrophage culture and cytokine measurements.
To
determine the effect of silicone gels and oils on macrophage cytokine
priming in vivo, peritoneal macrophages from four randomly selected
mice were pooled at the time of euthanasia. The cells were washed with
PBS and placed in a 24-well culture plate (2 × 105
cells per well in PBS). Lipopolysaccharide (LPS; Escherichia coli, serotype O111:B4; Sigma) was added at 0.5, 5.0, or 25 ng/ml. PBS was added to a fourth set of wells and served as an unstimulated control. The cells were incubated for 16 h at 37°C, the plates were centrifuged, and the supernatants were collected and stored at
70°C until used. Mouse IL-6 and IL-1
were measured by employing commercial ELISA kits from R&D Systems (Minneapolis, Minn.).
Kidney histology and immunofluorescence.
Kidney pathology
was assessed as described previously (20). For light
microscopy, kidneys were fixed in formalin, dehydrated, and embedded in
paraffin, and 6-µm sections were cut and stained with hematoxylin and
eosin. For direct immunofluorescence, kidneys were snap frozen, and
5-µm cryostat sections were cut and stained with either
FITC-conjugated rabbit anti-mouse IgG (1:100 dilution), goat anti-mouse
IgM (1:100 dilution) (Sigma), or rabbit anti-mouse complement 3 (C3)
(1:300 dilution) (ICN, Auora, Ohio) antibodies. Sections were examined
with a epifluorescence microscope equipped with an FITC filter.
 |
RESULTS |
Anticytoplasmic and antinuclear autoantibodies.
Table
1 summarizes the frequency of
anticytoplasmic and antinuclear antibody production in A.SW mice 6 months after injection with either PBS, pristane, silicone gel, or
silicone oil. Antibodies against ribosomal P, nRNP/Sm, and Su antigens
are lupus-associated autoantibodies produced by BALB/c and
other strains of mice treated with pristane (5,
18-21). As expected, pristane induced all of these specificities
in A.SW mice, as well as anti-ssDNA antibodies. In contrast, mice
treated with PBS, silicone gel, or silicone oil did not produce
anti-nRNP/Sm, -Su or -ribosomal P antibodies. However, three of the
silicone oil-treated mice produced relatively low levels IgG
anti-ssDNA. Five silicone gel- and nine silicone oil-treated mice
showed a positive FANA reaction. However, this result was not
statistically significant because four of the PBS-treated mice also
were FANA positive. Table 2 shows the
frequency of IgG antichromatin antibodies production over time. At 6 months, one silicone gel and three silicone oil-treated mice produced IgG antichromatin antibodies at levels three to eight times
greater than the highest value from the PBS-treated mice. However,
on average, only pristane-treated mice produced significant
amounts of IgG antichromatin antibodies at between 2 and 5 months.
Immunoglobulin levels.
To determine whether silicones affected
immunoglobulin production in a nonspecific manner, we examined the
major immunoglobulin isotypes. Figure 1A
through E shows the mean serum levels and time courses of IgM, IgG1,
IgG2a, IgG2b, and IgG3, respectively, from mice treated with PBS,
pristane, silicone gel, and silicone oil. As expected, there was a
general increase in all immunoglobulins measured over time in mice
treated with PBS, a result probably reflecting the normal response to
microbial stimulation (5). Pristane-treated mice showed a
significant rise in IgM levels (Fig. 1A) within 1 month of injection;
these levels began to decline and then followed a course parallel to
those of the PBS-treated mice. Silicone gel- and silicone oil-treated
mice showed a significant rise in IgM levels within 2 months of
injection, and these levels remained elevated for a prolonged period in
contrast to the pristane-induced IgM levels. IgG1 (Fig. 1B) serum
levels tended to become significantly elevated at 4 months for silicone
gel- and silicone oil-treated mice, while the pristane-treated mice
showed significant elevations at 5 and 6 months. IgG2a levels increased
dramatically in pristane-treated mice (Fig. 1C) compared to all other
mice. However, lower but still significant elevations were seen in the
silicone oil-treated mice (Fig. 1C) at 6 months. IgG2b (Fig. 1D) levels
were only elevated in pristane-treated mice at 5 and 6 months. IgG3
(Fig. 1E) levels became significantly elevated only in silicone
oil-treated mice between 4 and 6 months.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
Mean serum IgM (A), IgG1 (B), IgG2a (C), IgG2b
(D), and IgG3 (E) levels (± the standard error of the mean) from mice
treated with either PBS, pristane, silicone gel, or silicone oil over
time. (A) *, P < 0.05 for pristane versus PBS at 1 month, silicone oil versus PBS at 1 through 6 months, and silicone gel
versus PBS at 4 months. (B) *, P < 0.05 for silicone
oil and silicone gel versus PBS at 4 months and pristane versus PBS at
5 and 6 months. (C) *, P < 0.05 for pristane versus
PBS at 2 through 6 months and silicone oil versus PBS at 6 months. (D)
*, P < 0.05 for pristane versus PBS at 5 and 6 months. (E) *, P < 0.05 for silicone oil versus PBS
at 4 through 6 months.
|
|
IL-6 and IL-1
secreted from mouse peritoneal macrophages.
Since we had previously observed that silicones activate
monocytes/macrophages in vitro (13), this experiment
afforded us an opportunity to study the effects of silicone on
macrophages in vivo. The production of IL-6 and IL-1
by pooled
peritoneal macrophages from mice treated with silicone oil, silicone
gel, pristane, or PBS are presented in Fig.
2A and B, respectively. Since the data
represent a single measurement for each bar, only qualitative
comparisons can be made. Under nonstimulating conditions, macrophages
from PBS-treated mice secreted little IL-6 (Fig. 2A), while pristane-,
silicone oil-, and silicone gel-treated mice spontaneously secreted
IL-6. Macrophages from PBS-treated mice, cultured with suboptimal
amounts of LPS, produced low amounts of IL-6. In contrast, macrophages
from pristane-, silicone gel-, and silicone oil-treated mice produced
much greater amounts of IL-6 when cultured with LPS in a dose-dependent
manner. IL-1
(Fig. 2B) was produced spontaneously from all sampled
mouse macrophages, with pristane-treated mice producing the greatest
amount. There was generally increased production of IL-1
from
macrophages collected from pristane-, silicone gel-, and silicone
oil-treated mice when cultured with increasing amounts of LPS. However,
this trend was not as pronounced as that seen with IL-6. Although each
datum point represents a single cytokine measurement (Fig. 2), there appears nonetheless to be a dose response to LPS, especially for IL-6
(Fig. 2A).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
IL-6 (A) and IL-1 (B) secreted from peritoneal
macrophages pooled from four mice from each treatment group and
cultured overnight in PBS with 0, 0.5, 5.0, or 25 ng of LPS per ml.
|
|
Kidney pathology.
No significant immune-complex
glomerulonephritis was observed by light microscopy in mice treated
with either pristane, silicone gel, or silicone oil compared to the PBS
control mice. Immunofluorescence revealed no significant deposition of
IgM, IgG, or C3 in glomeruli from the experimental mice compared with
the PBS control mice. We noted that a few kidney sections from mice
treated with either silicone gel or oil had large vacuoles within some
of their glomeruli. Although we do not have definitive analytical
evidence, we speculate that these vacuoles once contained silicone that
was washed out during histological processing. Curiously, these
vacuoles were not observed in kidney sections obtained from
pristane-treated mice.
 |
DISCUSSION |
The immunological response to silicones is not fully understood.
When mixed with an antigen, silicone gel behaves as a potent humoral
adjuvant but does not enhance CMI (9). In comparison, low-MW
silicone oils are generally weak adjuvants. The lack of adjuvancy by
silicone oils has been ascribed to their inability to form an optimal
emulsion with an antigen, in contrast to the more efficient formation
of an emulsion with silicone gels (12). Because low-MW
silicone oils are poor adjuvants, we had assumed that only ruptured
silicone gel-filled implants may pose a health risk. More recently,
however, we demonstrated that both silicone gel and silicone oil (1,000 cs) can activate monocytes in vitro to overproduce proinflammatory
cytokines (IL-6, IL-1
, and TNF-
) (13). Thus, our
revised working hypothesis is that both silicone gels and silicone oils
incite a chronic inflammation both locally and systemically. This
chronic inflammatory response may perturb immune regulatory pathways,
but it is unlikely to lead to classic autoimmunity, e.g., rheumatoid
arthritis, systemic lupus erythematosus, and scleroderma, at least in
individuals without genetic susceptibility. This hypothesis is
supported by the present investigations. However, the question of
whether or not these materials can exacerbate autoimmunity in mice
predisposed to lupus-like disease (8) was not examined here.
Induction of hypergammaglobulinemia by silicone oil or gel.
Polyclonal hypergammaglobulinemia was perhaps the most striking
abnormality induced by the intraperitoneal administration of silicone
oil and silicone gel. The increased level of IgG3 induced by silicone
oil and the increased total IgM level induced by both gel and oil was
even higher than that seen in pristane-treated mice, whereas the
increased levels of IgG1 were comparable. In contrast, pristane induced
far higher levels of IgG2a and IgG2b than silicone oil or gel. The
preferential increase in IgM and IgG3 is consistent with the first
phase of immunoglobulin production induced by pristane (20).
In pristane-induced lupus, this early phase has been hypothesized to
reflect polyclonal B-1 cell activation and expansion (15).
However, the comparable levels of IgG1, a T-cell-dependent isotype,
induced by silicone gels and oils and pristane suggest that there may
be effects on conventional B cells as well. This may be mediated by
IL-4 (23). In contrast to silicone gels and oils, pristane
appears to be far more potent at inducing the production of IgG2a
autoantibodies, suggesting that pristane may stimulate gamma interferon
(IFN-
) production more efficiently (23). Recent data are
consistent with the importance of IFN-
in the pathogenesis of
pristane-induced lupus (H. B. Richards et al., manuscript in preparation).
Enhancement of IL-6 and IL-1
production.
A second immune
effect of intraperitoneal silicone oil or gel administration is the
enhancement of IL-6 and IL-1
production by peritoneal macrophages.
Silicone oil, silicone gel, and pristane all appear to prime these
cells to overproduce IL-6 and IL-1
in response to LPS. This result
is consistent with previous observations that silicones preabsorbed
with protein activate monocytes in vitro (13). We ascribed
this activation to the very hydrophobic nature of silicones, since
polystyrene, preadsorbed with protein, also can activate monocytes in
vitro (13). Thus, IL-6 and IL-1
may play a role in
mediating the inflammatory response to silicones. Moreover, IL-6 may be
involved in the pathogenesis of the hypergammaglobulinemia. This
cytokine has well-known effects on immunoglobulin production and plasma
cell differentiation (1) and is critical for the production
of anti-DNA and antichromatin autoantibodies by pristane-treated BALB/c
mice (16). In contrast, the production of anti-nRNP/Sm and
Su autoantibodies is less IL-6 dependent. It is of interest, therefore,
that silicone gels and oils augment spontaneous, as well as
LPS-inducible, IL-6 overproduction by peritoneal macrophages along with
the production of high levels of anti-DNA and antichromatin autoantibodies in at least some mice (Table 2).
Induction of autoantibodies by silicone oil or gel.
In
contrast, none of the silicone gel- or oil-treated mice produced
anti-nRNP/Sm, Su, or ribosomal P autoantibodies, whereas all of these
specificities were produced by pristane-treated A.SW mice. We speculate
that this may be related to the inefficient stimulation of
IFN-
production by silicones, as reflected in the markedly
lower total IgG2a levels compared to pristane-treated mice (Fig. 1C).
In support of this interpretation is evidence that the frequency of
anti-nRNP/Sm autoantibodies is greatly reduced in IFN-
-deficient
compared with wild-type or IL-4-deficient BALB/c mice (Richards et al.,
in preparation).
The presence of suspected silicone droplets in the glomeruli of
some mice 6 months after treatment is an indicator of silicone's
durability and capacity for systemic dissemination throughout
the host.
These suspected droplets of silicone would likely present
a large
effective surface area, allowing for persistent macrophage
activation
and the expression of proinflammatory
cytokines.
In conclusion, the present studies suggest that the intraperitoneal
administration of silicone oils or silicone gels induces
some of the
abnormalities typical of pristane-induced lupus in
mice. Polyclonal
IgM, IgG3, and IgG1 hypergammaglobulinemia, as
well as overproduction
of IL-6 and IL-1

, are especially prominent.
However, in contrast to
pristane-induced lupus, there is a quantitative
difference in the
stimulation of IgG2a production, a difference
presumably related to
lower levels of IFN-

. This may be responsible
for the relatively
poor efficacy of silicone gels and oils in
stimulating autoantibody
production. Nevertheless, the high levels
of antichromatin
autoantibodies produced by some of the mice suggest
that in some cases
chronic immune stimulation by silicone gels
and oils may lead to the
production of a subset of autoantibodies,
although not the full
spectrum seen in pristane-treated mice.
These observations may be
relevant to understanding the vague
and often poorly defined
autoimmune-like phenomena occurring in
certain individuals with
silicone implants. However, further experimental
and clinical studies
will be necessary to address this
question.
 |
ACKNOWLEDGMENTS |
This work was supported by U.S. Public Health Service
grants AI34597, AR44731, AI44074, P60-AR30701, and
T32-AR7416.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Surgery, Rochester General Hospital, 1425 Portland Ave., Rochester, NY 14621. Phone: (716) 338-4662. Fax: (716) 338-3442. E-mail:
john.naim{at}viahealth.org.
 |
REFERENCES |
| 1.
|
Akira, S.,
T. Taga, and T. Kishimoto.
1993.
Interleukin-6 in biology and medicine.
Adv. Immunol.
54:1-78[Medline].
|
| 2.
|
Edworthy, S. M.,
L. Martin,
S. G. Barr,
D. C. Birdsell,
R. F. Brant, and M. J. Fritzler.
1998.
A clinical study of the relationship between silicone breast implants and connective tissue disease.
J. Rheumatol.
25:254-260[Medline].
|
| 3.
|
Gabriel, S. E.,
W. M. O'Fallon,
L. T. Kurland,
C. M. Beard,
J. E. Woodsand, and L. J. Melton.
1994.
Risk of connective-tissue diseases and other disorders after breast implantation.
N. Engl. J. Med.
330:1697-1702[Abstract/Free Full Text].
|
| 4.
|
Glantz, S. A. (ed.).
1992.
Primer of biostatistics, 3rd ed., p. 110-154.
McGraw-Hill, New York, N.Y.
|
| 5.
|
Hamilton, K. J.,
M. Satoh,
J. Swartz,
H. B. Richards, and W. H. Reeves.
1998.
Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus.
Clin. Immunol. Immunopathol.
86:271-279[CrossRef][Medline].
|
| 6.
|
Hennekens, C. H.,
I. Lee,
N. R. Cook,
P. R. Hebert,
E. W. Karlson,
F. LaMotte,
J. E. Manson, and J. E. Buring.
1996.
Self-reported breast implants and connective-tissue diseases in female health professionals.
JAMA
275:616-621[Abstract/Free Full Text].
|
| 7.
|
Lane, T. H., and S. A. Burns.
1996.
Silica, silicon, and silicone ... unraveling the mystery.
Curr. Top. Microbiol. Immunol.
210:3-12[Medline].
|
| 8.
|
McDonald, A. H.,
K. Weir,
M. Schneider,
L. Gudenkuaf, and J. R. Sanger.
1998.
Silicone gel enhances the development of autoimmune disease in New Zealand black mice but fails to induce it in BALB/cAnPt mice.
Clin. Immunol. Immunopathol.
87:248-255[CrossRef][Medline].
|
| 9.
|
Naim, J. O.,
R. J. Lanzafame, and C. J. van Oss.
1993.
The effect of silicone-gel on antibody formation in rats.
Immunol. Investig.
22:151-161[Medline].
|
| 10.
|
Naim, J. O.,
K. M. Ippolito,
R. J. Lanzafame, and C. J. van Oss.
1995.
The effect of molecular weight and gel preparation on humoral adjuvancy of silicone oils and silicone gels.
Immunol. Investig.
24:537-547[Medline].
|
| 11.
|
Naim, J. O.,
K. M. Ippolito,
R. J. Lanzafame, and C. J. van Oss.
1995.
Induction of type II collagen arthritis in the DA rat using silicone gels and oils as adjuvant.
J. Autoimmunity
8:751-761[CrossRef][Medline].
|
| 12.
|
Naim, J. O.,
K. M. L. Ippolito, and C. J. van Oss.
1997.
Adjuvancy effect of different types of silicone gel.
J. Biomed. Materials Res.
37:534-538[CrossRef].
|
| 13.
|
Naim, J. O.,
C. J. van Oss,
K. M. L. Ippolito,
J.-W. Zhang,
L.-P. Jin,
R. Fortuna, and N. A. Buehner.
1998.
In vitro activation of human monocytes by silicones.
Colloids Surfaces B Biointerfaces
11:79-86[CrossRef].
|
| 14.
|
Park, A. J.,
R. J. Black,
N. S. Sarhadi,
U. Chetty, and A. C. Watson.
1998.
Silicone gel filled breast implants and connective tissue diseases.
Plastic Reconstruct. Surg.
101:261-268[Medline].
|
| 15.
|
Richards, H. B.,
M. Satoh,
J. C. Jennette,
T. Okano,
Y. S. Kanwar, and W. H. Reeves.
1999.
Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice.
Clin. Exp. Immunol.
115:547-553[CrossRef][Medline].
|
| 16.
|
Richards, H. B.,
M. Satoh,
M. Shaw,
C. Libert,
V. Poli, and W. H. Reeves.
1998.
Interleukin-6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus.
J. Exp. Med.
188:985-990[Abstract/Free Full Text].
|
| 17.
|
Sanchez-Guerrero, J.,
G. A. Colditz,
E. W. Karlson,
D. J. Hunter,
F. E. Speizer, and M. H. Liang.
1995.
Silicone breast implants and the risk of connective-tissue diseases and symptoms.
N. Engl. J. Med.
332:1666-1670[Abstract/Free Full Text].
|
| 18.
|
Satoh, M.,
K. J. Hamilton,
A. K. Ajmani,
X. Dong,
J. Wang,
Y. S. Kanwar, and W. H. Reeves.
1996.
Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in SJL mice treated with pristane.
J. Immunol.
157:3200-3206[Abstract].
|
| 19.
|
Satoh, M., and W. H. Reeves.
1994.
Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane.
J. Exp. Med.
180:2341[Abstract/Free Full Text].
|
| 20.
|
Satoh, M.,
A. Kumar,
Y. S. Kanwar, and W. H. Reeves.
1995.
Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane.
Proc. Natl. Acad. Sci. USA
92:10934-10938[Abstract/Free Full Text].
|
| 21.
|
Satoh, M.,
E. L. Treadwell, and W. H. Reeves.
1995.
Pristane induces high titers of anti-Su and anti-nRNP/Sm autoantibodies in BALB/c mice: quantitation by antigen capture ELISAs based on monospecific human autoimmune sera.
J. Immunol. Methods
182:51-62[CrossRef][Medline].
|
| 22.
|
Schwartz, R. S.
1993.
Autoimmunity and autoimmune diseases, p. 1064-1065.
In
W. E. Paul (ed.), Fundamental immunology, 3rd ed. Raven Press, New York, N.Y.
|
| 23.
|
Snapper, C. M., and W. E. Paul.
1987.
Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production.
Science
236:944-947[Abstract/Free Full Text].
|
Clinical and Diagnostic Laboratory Immunology, May 2000, p. 366-370, Vol. 7, No. 3
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Thomas, L. R., Miyashita, H., Cobb, R. M., Pierce, S., Tachibana, M., Hobeika, E., Reth, M., Shinkai, Y., Oltz, E. M.
(2008). Functional Analysis of Histone Methyltransferase G9a in B and T Lymphocytes. J. Immunol.
181: 485-493
[Abstract]
[Full Text]
-
Kuroda, Y., Akaogi, J., Nacionales, D. C., Wasdo, S. C., Szabo, N. J., Reeves, W. H., Satoh, M.
(2004). Distinctive Patterns of Autoimmune Response Induced by Different Types of Mineral Oil. Toxicol Sci
78: 222-228
[Abstract]
[Full Text]